Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Ericsson

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Arthritis Research & Therapy|July 31, 2016
Resistance exercise improves physical fatigue in women with fibromyalgia: a randomized controlled trialAnna Ericsson, Annie Palstam, Anette Larsson, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Thienopyrrole acetic acids as antagonists of the CRTH2 receptorDominique Bonafoux, Ayome Abibi, Brian Bettencourt, et al.
Blood|January 5, 2006
Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestineHanna Stenstad, Anna Ericsson, Bengt Johansson-Lindbom, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2008
Synthesis and in vitro activity of N'-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonistsMichael J Morytko, Patrick Betschmann, Kevin Woller, et al.
Contemporary Clinical Trials Communications|September 30, 2024
Treatment effects of two pharmaceutical skin care creams for xerotic feet among persons with diabetes: Rationale and design of a two-armed double blind randomized controlled trialAnna Ericsson, Karin Borgström, Christine Kumlien, et al.
Experimental Hematology|November 16, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell diseaseAnna Ericsson, David J Richard, Erik Wilker, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2012
Design and synthesis of tricyclic cores for kinase inhibitionStacy Van Epps, Bryan Fiamengo, Jeremy Edmunds, et al.
Molecular Cancer Therapeutics|September 5, 2024
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in CancerRobinson Triboulet, Khikmet Sadykov, Darren M Harvey, et al.
Journal of Medicinal Chemistry|January 24, 2020
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 InhibitorJustin A Caravella, Jian Lin, R Bruce Diebold, et al.
Journal of Medicinal Chemistry|June 15, 2019
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) InhibitorsJian Lin, Wei Lu, Justin A Caravella, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Arthritis Research & Therapy|July 31, 2016
Resistance exercise improves physical fatigue in women with fibromyalgia: a randomized controlled trialAnna Ericsson, Annie Palstam, Anette Larsson, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Thienopyrrole acetic acids as antagonists of the CRTH2 receptorDominique Bonafoux, Ayome Abibi, Brian Bettencourt, et al.
Blood|January 5, 2006
Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestineHanna Stenstad, Anna Ericsson, Bengt Johansson-Lindbom, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2008
Synthesis and in vitro activity of N'-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonistsMichael J Morytko, Patrick Betschmann, Kevin Woller, et al.
Contemporary Clinical Trials Communications|September 30, 2024
Treatment effects of two pharmaceutical skin care creams for xerotic feet among persons with diabetes: Rationale and design of a two-armed double blind randomized controlled trialAnna Ericsson, Karin Borgström, Christine Kumlien, et al.
Experimental Hematology|November 16, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell diseaseAnna Ericsson, David J Richard, Erik Wilker, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2012
Design and synthesis of tricyclic cores for kinase inhibitionStacy Van Epps, Bryan Fiamengo, Jeremy Edmunds, et al.
Molecular Cancer Therapeutics|September 5, 2024
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in CancerRobinson Triboulet, Khikmet Sadykov, Darren M Harvey, et al.
Journal of Medicinal Chemistry|January 24, 2020
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 InhibitorJustin A Caravella, Jian Lin, R Bruce Diebold, et al.
Journal of Medicinal Chemistry|June 15, 2019
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) InhibitorsJian Lin, Wei Lu, Justin A Caravella, et al.
Pageof 3